Access to plasma viral load in people living with HIV under treatment in Ouagadougou and Bobo Dioulasso, Burkina Faso.

Objectives: Less than 25% of people living with HIV (PLWHIV) achieved plasma viral load (PVL) in 2020 in Burkina Faso. This study aimed to identify factors associated with access to PVL in Ouagadougou and Bobo-Dioulasso.

Methods: A cross-sectional analytical study was conducted among PLWHIV in Burkina Faso between April 15 and August 8, 2022.

[Factors associated with venous thromboembolism in tuberculosis patients in Burkina Faso: A case control study].

Introduction: The mortality caused by tuberculosis is partially explained by co-morbidities such as venous thromboembolic disease. Our study was aimed at identifying the factors associated with venous thromboembolism in tuberculosis patients.

Methods: This was a case-control study of patients with pulmonary tuberculosis with or without venous thromboembolic disease.

Assessing customer satisfaction: the case of test prescribers at the clinical biology laboratory of Centre Muraz/ Institut National de Santé Publique, Burkina Faso.

Context: Assessing customer satisfaction with a product or service is one technique for evaluating the quality of a product or service given by a company. One of the instruments used to gauge customer satisfaction is the satisfaction survey. The Clinical Biology Laboratory of Centre Muraz employed this method to determine how satisfied its test prescribers were to improve.

Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.

Background: Malaria remains a substantial public health burden among young children in sub-Saharan Africa and a highly efficacious vaccine eliciting a durable immune response would be a useful tool for controlling malaria. R21 is a malaria vaccine comprising nanoparticles, formed from a circumsporozoite protein and hepatitis B surface antigen (HBsAg) fusion protein, without any unfused HBsAg, and is administered with the saponin-based Matrix-M adjuvant. This study aimed to assess the safety and immunogenicity of the malaria vaccine candidate, R21, administered with or without adjuvant Matrix-M in adults naïve to malaria infection and in healthy adults from malaria endemic areas.

Salivary extracellular vesicles isolation methods impact the robustness of downstream biomarkers detection.

Extracellular vesicles (EVs), crucial mediators in cell-to-cell communication, are implicated in both homeostatic and pathological processes. Their detectability in easily accessible peripheral fluids like saliva positions them as promising candidates for non-invasive biomarker discovery. However, the lack of standardized methods for salivary EVs isolation greatly limits our ability to study them.